万珂在高危骨髓瘤应用及万珂再治疗.pptVIP

* Results Results for all patients (n=43) CR + PR 72.5%, CR 40% 7 patients did not respond 10 patients relapsed after 18 months of stable response Of these, 12 pts received bortezomib + dex 5 pts received bortezomib + mel + pred Response to bortezomib + dex: 1 CR, 7 PR Response to bortezomib + mel + pred 1 CR, 2 PR Adverse events Thrombocytopenia (38.4%), fatigue 38.5%, PN 33.3%, constipation 35.8% * 初次和再次治疗的万珂联合方案是否不同？ /medicalnews.php?newsid=58681nfid=al Utility of VELCADE (Bortezomib) Retreatment for Patients with Relapsed Multiple MyelomaThe retrospective review of 22 patients primar